Breaking News Instant updates and real-time market news.

ALBO

Albireo Pharma

$17.05

0.1 (0.59%)

, BNCN

BNC Bancorp

08:30
06/19/17
06/19
08:30
06/19/17
08:30

Twelve option delistings on June 19th

Option delistings effective June 19th include Aixtron SE (ADS) (AIXNY), Albireo (ALBO), AVG Technologies NV (AVGTF), BNC Bancorp (BNCN), AM Castle and Company Inc (CASL), Eca Marcellus (ECT), First Defiance Financial (FDEF), UBS Natural Gas Subindex (GAZ), Immune Design (IMDZ), Lifetime Brands (LCUT), Luxottica (LUX), and Yahoo (YHOO).

ALBO

Albireo Pharma

$17.05

0.1 (0.59%)

BNCN

BNC Bancorp

CASL

Castle Dental Centers

ECT

ECA Marcellus

$2.15

0.1 (4.88%)

FDEF

First Defiance Financial

$53.92

-0.89 (-1.62%)

IMDZ

Immune Design

$7.20

0.05 (0.70%)

LCUT

Lifetime Brands

$17.95

-0.25 (-1.37%)

LUX

Symbol now LUXTY

YHOO

Tag AABA

  • 21

    Jun

  • 18

    Sep

  • 28

    Sep

ALBO Albireo Pharma
$17.05

0.1 (0.59%)

01/25/17
WBLR
01/25/17
INITIATION
WBLR
Outperform
Albireo Pharma initiated with an Outperform at William Blair
William Blair analyst Y. Katherine Xu started Albireo Pharma with an Outperform rating. The company's A4250 has a "strong chance of success" in becoming the standard of care in progressive familial intrahepatic cholestasis, Xu tells investors in a research note. She derives a fair value for Albireo shares of $70 at the end of 2017. The stock closed yesterday at $18.50.
02/16/17
LTCO
02/16/17
INITIATION
Target $40
LTCO
Buy
Albireo Pharma initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Matt Kaplan started Albireo Pharma with a Buy rating and $40 price target. The analyst views Albireo's lead product as A4250, which is currently in Phase 2 development for treatment of cholestatic liver diseases in pediatric patients. Kaplan says the company has a "solid" pipeline of programs with multiple catalysts and projected total peak sales of over $975M.
02/16/17
02/16/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Salesforce (CRM) initiated with a Hold at Needham by analyst Scott Berg, who cites decelerating organic revenue growth, a looming sales reorganization, and an operating model not profitable enough at its revenue to drive valuation higher. 2. BioCryst (BCRX) initiated with a Buy at Ladenburg by analyst Christopher James, who thinks the company is poised to become a leading oral drug rare disease company. 3. Seaport Global analyst Josh Sullivan started CACI (CACI) International with a Buy rating and $140 price target. The company has broad exposure to trends in fiscal/defense spending, the analyst contends. 4. Citi analyst Walter Pritchard started OpenText (OTEX) with a Neutral rating and $36 price target, stating that the current valuation already reflects the potential of the ECD acquisition. 5. Albireo Pharma (ALBO) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BNCN BNC Bancorp

11/16/16
11/16/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Intuit (INTU) assumed with a Hold at Evercore ISI. 2. BNC Bancorp (BNCN) initiated with an Overweight at Piper Jaffray. 3. Cooper Tire (CTB) coverage resumed with an Overweight at KeyBanc. 4. Lithia Motors (LAD) coverage resumed with an Overweight at KeyBanc. 5. Nielsen (NLSN) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/22/16
SDLR
11/22/16
DOWNGRADE
Target $32
SDLR
Hold
BNC Bancorp downgraded to Hold from Buy at Sandler O'Neill
Sandler O'Neill analyst Stephen Scouten downgraded BNC Bancorp to Hold citing the recent strong move in shares and raised its price target to $32.
11/29/16
KBWI
11/29/16
DOWNGRADE
Target $32
KBWI
Market Perform
BNC Bancorp downgraded to Market Perform from Outperform at Keefe Bruyette
Keefe Bruyette analyst Brady Gailey downgraded BNC Bancorp to Market Perform citing valuation with the stock up 23% since November 8. The analyst raised his price target for the shares to $32 from $26.50.
01/25/17
SPHN
01/25/17
DOWNGRADE
SPHN
Equal Weight
BNC Bancorp downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Tyler Stafford downgraded BNC Bancorp (BNCN) to Equal Weight from Overweight after the company agreed to merge with and into Pinnacle Financial Partners (PNFP) in an all-stock transaction.
CASL Castle Dental Centers

ECT ECA Marcellus
$2.15

0.1 (4.88%)

FDEF First Defiance Financial
$53.92

-0.89 (-1.62%)

IMDZ Immune Design
$7.20

0.05 (0.70%)

LCUT Lifetime Brands
$17.95

-0.25 (-1.37%)

12/15/16
SIDC
12/15/16
DOWNGRADE
Target $19
SIDC
Neutral
Lifetime Brands downgraded to Neutral from Buy at Sidoti
Sidoti analyst Frank Camma downgraded Lifetime Brands to Neutral citing valuation and the "tepid" retail environment. The analyst keeps a $19 price target for the shares.
02/10/17
SIDC
02/10/17
UPGRADE
Target $19
SIDC
Buy
Lifetime Brands upgraded to Buy from Neutral at Sidoti
Sidoti analyst Frank Camma upgraded Lifetime Brands to Buy from Neutral saying that its valuation has become compelling as its restructuring and acquisitions are poised to drive earnings growth. The analyst keeps a $19 price target on Lifetime shares.
03/16/17
SIDC
03/16/17
DOWNGRADE
Target $19
SIDC
Neutral
Lifetime Brands downgraded to Neutral from Buy at Sidoti
Sidoti analyst Frank Camma downgraded Lifetime Brands to Neutral with the stock above his unchanged price target of $13 following Mill Road Capital's offer.
05/26/17
SIDC
05/26/17
UPGRADE
SIDC
Buy
Lifetime Brands upgraded to Buy from Neutral at Sidoti
LUX Symbol now LUXTY

09/29/16
BOFA
09/29/16
NO CHANGE
Target $41
BOFA
Underperform
Luxottica faces significant headwinds, added to Q4 Top Ideas at BofA/Merrill
BofA/Merrill analyst Ashley Wallace expects weak retail and wholesale sales trends from Luxottica's Q3 earnings report October 24. The analyst expects earnings downgrades to follow and for multiple pressure. Wallace remains concerned about Luxottica reduced brand momentum, increased competition, the highly promotional business environment, and loss of control over distribution. She reiterates her Underperform rating and $41 price target and added Luxottica to BofA/Merrill's Q4 EMEA Top Ideas list.
01/05/17
SOCG
01/05/17
DOWNGRADE
SOCG
Hold
Luxottica downgraded to Hold from Buy at Societe Generale
01/17/17
GSCO
01/17/17
UPGRADE
GSCO
Neutral
Luxottica upgraded to Neutral from Sell at Goldman
Goldman analyst Jamie Bajwa upgraded Luxottica from Sell to Neutral on the belief that the announcement of its proposed merger with Essilor increases the M&A expectations for Luxottica. The firm's target on Luxottica was raised to EUR 57.8 from EUR 40.5.
01/27/17
HSBC
01/27/17
UPGRADE
HSBC
Buy
Luxottica upgraded to Buy from Hold at HSBC
YHOO Tag AABA

04/19/17
OPCO
04/19/17
NO CHANGE
Target $57
OPCO
Outperform
Yahoo price target raised to $57 from $52 at Oppenheimer
Oppenheimer analyst Jason Helfstein raised his price target for Yahoo to $57 from $52 after the company reported Q1 earnings. The analyst reiterates an Outperform rating on the shares.
04/21/17
OPCO
04/21/17
NO CHANGE
OPCO
Perform
Verizon responding to wireless competition, says Oppenheimer
Oppenheimer analyst Timothy Horan expects Verizon's (VZ) equipment revenue in Q4 to be strong, linked to the release of the new iconic Apple (AAPL) iPhone 8. The analyst believes wireless competition will remain elevated, but Verizon is responding, and will remained focused on network quality. Further, Horan says Verizon is integrating Yahoo (YHOO)/AOL to deliver growth from programmatic ads/digital content, but this will take some time. He reiterates a Perform rating on Verizon's shares.
06/09/17
BOFA
06/09/17
NO CHANGE
Target $70
BOFA
Buy
Yahoo price target raised to $70 from $58 at BofA/Merrill
BofA/Merrill analyst Jusin Post raised Yahoo's (YHOO) price target to $70 from $58 to reflect a revised sum-of-the-parts valuation following Alibaba's (BABA) increased sales forecast and analyst Eddie Leung's revised price target on shares to $161 from $125.
06/14/17
RAJA
06/14/17
NO CHANGE
Target $72
RAJA
Yahoo price target raised to $72 from $58 at Raymond James

TODAY'S FREE FLY STORIES

XRAY

Dentsply Sirona

$65.65

-0.14 (-0.21%)

07:47
01/17/18
01/17
07:47
01/17/18
07:47
Hot Stocks
Dentsply Sirona adds three new board members »

Dentsply Sirona has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:47
01/17/18
01/17
07:47
01/17/18
07:47
General news
Futures suggest rebound from yesterday's dip »

Stock futures are higher…

PSO

Pearson

$9.82

-0.08 (-0.81%)

07:47
01/17/18
01/17
07:47
01/17/18
07:47
Hot Stocks
Pearson: U.S. tax reform to result in one-off deferred tax charge in 2017 »

Pearson says, "Our…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSO

Pearson

$9.82

-0.08 (-0.81%)

07:46
01/17/18
01/17
07:46
01/17/18
07:46
Hot Stocks
Pearson sees FY18 adjusted operating profit GBP520M-GBP560M »

Pearson says, "In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WIFI

Boingo Wireless

$21.49

-0.83 (-3.72%)

07:46
01/17/18
01/17
07:46
01/17/18
07:46
Initiation
Boingo Wireless initiated  »

Boingo Wireless initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

PSO

Pearson

$9.82

-0.08 (-0.81%)

07:46
01/17/18
01/17
07:46
01/17/18
07:46
Earnings
Pearson sees FY adjusted EPS above 49p-52p guidance range »

Adjusted earnings per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADNT

Adient

$81.91

-0.51 (-0.62%)

07:45
01/17/18
01/17
07:45
01/17/18
07:45
Technical Analysis
Technical Take: Adient falls sharply in pre-market, analyst action »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

ESPR

Esperion

$71.91

-1.35 (-1.84%)

07:45
01/17/18
01/17
07:45
01/17/18
07:45
Recommendations
Esperion analyst commentary  »

Esperion price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$68.78

-0.48 (-0.69%)

07:44
01/17/18
01/17
07:44
01/17/18
07:44
Recommendations
Lennar analyst commentary  »

Lennar price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NHYDY

Norsk Hydro

$7.60

-0.16 (-2.06%)

07:43
01/17/18
01/17
07:43
01/17/18
07:43
Downgrade
Norsk Hydro rating change  »

Norsk Hydro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FAST

Fastenal

$55.44

-0.15 (-0.27%)

07:43
01/17/18
01/17
07:43
01/17/18
07:43
Earnings
Fastenal reports Q4 EPS 45c ex-tax benefit, consensus 45c »

Management said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

LBTYA

Liberty Global

$36.56

-0.31 (-0.84%)

07:43
01/17/18
01/17
07:43
01/17/18
07:43
Upgrade
Liberty Global rating change  »

Liberty Global upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

, CELG

Celgene

$104.82

-1.18 (-1.11%)

07:42
01/17/18
01/17
07:42
01/17/18
07:42
Recommendations
Juno Therapeutics, Celgene analyst commentary  »

Juno Therapeutics price…

JUNO

Juno Therapeutics

$45.60

-3.15 (-6.46%)

CELG

Celgene

$104.82

-1.18 (-1.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

GS

Goldman Sachs

$258.46

1.43 (0.56%)

07:42
01/17/18
01/17
07:42
01/17/18
07:42
Hot Stocks
Goldman CEO: Global economy poised to accelerate, tax reform providing tailwinds »

"Last year, we…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

ONTX

Onconova

$1.74

-0.0901 (-4.92%)

07:42
01/17/18
01/17
07:42
01/17/18
07:42
Hot Stocks
Onconova increases sample size in Phase 3 INSPIRE pivotal trial in MDS »

Onconova is moving…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HALO

Halozyme

$19.74

-0.62 (-3.05%)

07:41
01/17/18
01/17
07:41
01/17/18
07:41
Technical Analysis
Technical Take: Halozyme drops in pre-market »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

07:41
01/17/18
01/17
07:41
01/17/18
07:41
Conference/Events
UBS oil services analyst holds an analyst/industry conference call »

Oil Services Analyst Wong…

GS

Goldman Sachs

$258.46

1.43 (0.56%)

07:41
01/17/18
01/17
07:41
01/17/18
07:41
Hot Stocks
Goldman Sachs reports Basel III CET1 ratio of 10.9% at December 31 »

The firm's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

C

Citi

$77.11

0.27 (0.35%)

07:40
01/17/18
01/17
07:40
01/17/18
07:40
Recommendations
Citi analyst commentary  »

Citi price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jan

  • 24

    Jan

GS

Goldman Sachs

$258.46

1.43 (0.56%)

07:38
01/17/18
01/17
07:38
01/17/18
07:38
Hot Stocks
Goldman Sachs reports Q4 net revenue in FICC sales & trading $1B »

Net revenues in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

SIG

Signet Jewelers

$56.79

-0.15 (-0.26%)

07:38
01/17/18
01/17
07:38
01/17/18
07:38
Periodicals
U.S. judge excludes 70,000 women from Sterling Jewelers lawsuit, Reuters says »

A U.S. judge has excluded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

GS

Goldman Sachs

$258.46

1.43 (0.56%)

07:37
01/17/18
01/17
07:37
01/17/18
07:37
Hot Stocks
Breaking Hot Stocks news story on Goldman Sachs »

Goldman Sachs says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

GG

Goldcorp

$15.39

1.04 (7.25%)

07:37
01/17/18
01/17
07:37
01/17/18
07:37
Downgrade
Goldcorp rating change  »

Goldcorp downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Feb

GS

Goldman Sachs

$258.46

1.43 (0.56%)

07:36
01/17/18
01/17
07:36
01/17/18
07:36
Earnings
Goldman Sachs reports Q4 EPS $5.68 ex Tax Legislation, consensus $4.92 »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

  • 18

    Jan

  • 31

    Jan

UNH

UnitedHealth

$232.90

4.26 (1.86%)

07:36
01/17/18
01/17
07:36
01/17/18
07:36
Recommendations
UnitedHealth analyst commentary  »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.